Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Lymphocytic Leukaemia: Update Bulletin [November 2015]

Product Code:
596200523
Publication Date:
November 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Chronic Lymphocytic Leukaemia (CLL). Topics covered include opinions about the possible use of Imbruvica (ibrutinib; AbbVie/Janssen) for patients with previously untreated CLL, and the extent to which Arzerra (ofatumumab; Novartis) is likely to be used within the maintenance setting for relapsed CLL. The potential role of TG Therapeutics’ novel triple therapy, containing TGR-1202, ublituximab (TG-1101) and Keytruda (pembrolizumab; Merck & Co.), in the treatment of refractory or relapsed CLL, is also discussed.

Key Questions Answered in this Update Bulletin:

  • To what extent will Imbruvica be used as a first-line treatment for CLL, assuming that it gains approval in this setting?
  • As Arzerra awaits US FDA approval as maintenance therapy for patients with relapsed CLL, will it be cost that proves critical for determining the agent’s level of success in this setting?
  • Do KOLs consider that TG Therapeutics’ novel triple therapy has the potential to become a useful treatment option for patients with relapsed or refractory CLL?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved